Immix Biopharma (NASDAQ:IMMX) Given “Buy” Rating at HC Wainwright

Immix Biopharma (NASDAQ:IMMX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $7.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 197.87% from the company’s previous close.

Immix Biopharma Stock Up 6.8 %

IMMX opened at $2.35 on Monday. The stock’s 50 day moving average price is $1.98 and its two-hundred day moving average price is $1.94. The firm has a market capitalization of $64.64 million, a P/E ratio of -2.76 and a beta of 0.28. Immix Biopharma has a 12-month low of $1.26 and a 12-month high of $6.87.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). As a group, analysts anticipate that Immix Biopharma will post -0.64 earnings per share for the current year.

Institutional Investors Weigh In On Immix Biopharma

An institutional investor recently raised its position in Immix Biopharma stock. Geode Capital Management LLC lifted its position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) by 5.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 150,082 shares of the company’s stock after purchasing an additional 7,954 shares during the quarter. Geode Capital Management LLC owned approximately 0.55% of Immix Biopharma worth $224,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.